Abstract:BACKGROUNDSARS-CoV is the causative agent of severe acute respiratory syndrome (SARS) which has been associated with outbreaks of SARS in Guangdong, Hong Kong and Beijing of China, and other regions worldwide. SARS-CoV from human has shown some variations but its origin is still unknown. The genotyping and phylogeny of SARS-CoV were analyzed and reported in this paper.METHODSFull or partial genomes of 44 SARS-CoV strains were collected from GenBank. The genotype, single nucleotide polymorphism and phylogeny of these SARS-CoV strains were analyzed by molecular biological, bioinformatic and epidemiological methods.RESULTSThere were 188 point mutations in the 33 virus full genomes with the counts of mutation mounting to 297. Further analysis was carried out among 36 of 188 loci with more than two times of mutation. All the 36 mutation loci occurred in coding sequences and 22 loci were non-synonymous. The gene mutation rates of replicase 1AB, S2 domain of spike glycoprotein and nucleocapsid protein were lower (0.079% - 0.103%). There were 4 mutation loci in S1 domain of spike glycoprotein. The gene mutation rate of ORF10 was the highest (3.333%) with 4 mutation loci in this small domain (120 bp) and 3 of 4 loci related to deletion mutation. By bioinformatics processing and analysis, the nucleotides at 7 loci of genome (T:T:A:G:T:C:T/C:G:G:A:C:T:C) can classify SARS-CoV into two types. Therefore a novel definition is put forward that according to these 7 loci of mutation, 40 strains of SARS-CoV in GenBank can be grouped into two genotypes, T:T:A:G:T:C:T and C:G:G:A:C:T:C, and named as SARS-CoV Yexin genotype and Xiaohong genotype. The two genotypes can be further divided into some sub-genotypes. These genotypes can also be approved by phylogenetic tree of three levels of 44 loci of mutation, spike glycoprotein gene and complete genome sequence. Compared to various strains among SARS-CoV Yexin genotype and Xiaohong genotype, GD01 strain of Yexin genotype is more closely related to SARS-CoV like-virus from animals.CONCLUSIONThe results mentioned above suggest that SARS-CoV is responding to host immunological pressures and experiencing variation which provide clues, information and evidence of molecular biology for the clinical pathology, vaccine developing and epidemic investigation.

Study on Molecular Biology of SRS Leukemia Virus Isolated in China and Inhibitory Effect of Antisense Oligodeoxynucleotides

Population Diversity of Rice Stripe Virus-Derived Sirnas in Three Different Hosts and RNAi-based Antiviral Immunity in Laodelphgax Striatellus.

Therapeutic and Prophylactic Potential of Small Interfering RNAs Against Severe Acute Respiratory Syndrome

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Inhibition of Severe Acute Respiratory Syndrome Virus Replication by Small Interfering RNAs in Mammalian Cells

Editorial: Novel Insights in RNA Modifications: from Basic to Translational Research

Establishment of Cell Clone of Lymphoma and a Cell Line Infected with Leukemia Virus and Study on Its Inducted Differentiation

Advances in the Study on Leukemia Strains and Leukemia Cell Lines in China

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference.

A DNA-based non-infectious replicon system to study SARS-CoV-2 RNA synthesis

Discovery and Functional Interrogation of the Virus and Host RNA Interactome of SARS-Cov-2 Proteins

Study on mechanism of antiviral effects on RSV of Xiaoer Shuangjin Qingre Oral Liquid

Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics

Study on the Inhibition of Specific 01igonucleotides on Classical Swine Fever Virus in Vitro

A Novel Cell Culture System Modeling the SARS-CoV-2 Life Cycle

Molecular Biological Analysis of Genotyping and Phylogeny of Severe Acute Respiratory Syndrome Associated Coronavirus.

In Vivo Structural Characterization of the SARS-CoV-2 RNA Genome Identifies Host Proteins Vulnerable to Repurposed Drugs.

Inhibition of Measles virus multiplication in cell culture by RNA interference

RNAi Therapeutics: Can Sirnas Conquer SARS?

A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma

Small Interfering Rna Inhibits Sars-Cov Nucleocapsid Gene Expression in Cultured Cells and Mouse Muscles